Nls pharmaceutics successfully appeals nasdaq delisting notice

Zurich, switzerland / accesswire / november 14, 2022 / nls pharmaceutics ltd. (nasdaq: nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that on november 11, 2022, it received a letter from the nasdaq hearings panel (the "panel"), indicating the panel's decision to grant the company's request to continue its listing on the nasdaq stock market llc ("nasdaq").
NLSP Ratings Summary
NLSP Quant Ranking